U.S. markets open in 9 hours 22 minutes
  • S&P Futures

    3,837.00
    -5.50 (-0.14%)
     
  • Dow Futures

    30,762.00
    -80.00 (-0.26%)
     
  • Nasdaq Futures

    13,548.25
    +62.75 (+0.47%)
     
  • Russell 2000 Futures

    2,131.50
    -14.30 (-0.67%)
     
  • Crude Oil

    52.80
    +0.19 (+0.36%)
     
  • Gold

    1,845.30
    -5.60 (-0.30%)
     
  • Silver

    25.40
    -0.14 (-0.56%)
     
  • EUR/USD

    1.2161
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    23.02
    -0.17 (-0.73%)
     
  • GBP/USD

    1.3732
    +0.0000 (+0.00%)
     
  • USD/JPY

    103.7170
    +0.0900 (+0.09%)
     
  • BTC-USD

    31,861.99
    +70.12 (+0.22%)
     
  • CMC Crypto 200

    641.23
    -6.09 (-0.94%)
     
  • FTSE 100

    6,654.01
    +15.16 (+0.23%)
     
  • Nikkei 225

    28,599.53
    +53.35 (+0.19%)
     

Cabaletta Bio to Present at Multiple August Investor Conferences

Cabaletta Bio
·2 min read

PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside chats at the following upcoming August investor conferences:

  • BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 1:00 p.m. ET.

  • Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 8:35 a.m. ET.

  • 40th Annual Canaccord Genuity Growth Conference on Wednesday, August 12, 2020 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTesTM phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com